Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Neuren Pharmaceuticals has reported Q1 2024 net sales of $75.9 million for their drug DAYBUE™, with full-year sales projected between $370-420 million. Approximately 25% of Rett syndrome patients in the U.S. have started treatment with DAYBUE™, showing strong persistence rates. The company is also making strides in international markets, with regulatory filings and reviews underway in Canada, Europe, and Japan.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
